Skip to content

BLUE CRESCENT · BMT & HAEMATOLOGY

Bone marrow & stem-cell transplantation

Haematology and BMT specialists at hospitals in Delhi and Gurugram

Transplant suitability, donor matching and treatment options require specialist assessment. Results and prices cannot be guaranteed before the case is evaluated.

Explore haematology and BMT doctorsRequest a report review

What is a stem-cell or bone marrow transplant?

Hematopoietic stem cells are infused through a vein to restore blood-cell formation after conditioning treatment or to manage selected blood disorders. The infusion is similar to a blood transfusion; it is not spinal surgery.

When can it be considered?

  • Selected acute or chronic leukaemias according to risk and stage
  • Lymphoma and multiple myeloma, sometimes with autologous transplant
  • Severe aplastic anaemia and selected bone marrow disorders (MDS)
  • Some cases of thalassaemia, sickle-cell disease, or inherited immune disorders

Not every patient with these conditions needs transplantation. The diagnosis, response, overall health and suitable donor availability matter.

Transplant types and cell sources

Autologous transplant

The patient’s own stem cells are collected before high-dose treatment and then reinfused, sometimes for myeloma or lymphoma. No external donor is used.

Allogeneic transplant

Stem cells come from an HLA-compatible related or unrelated donor. The team manages graft rejection and graft-versus-host disease (GVHD) risks.

Haploidentical transplant

A half-matched family member such as a parent or child may be eligible using specialised GVHD prevention protocols.

Cord blood, peripheral blood or marrow

Cells may be collected from peripheral blood by apheresis, from the pelvic bone under anaesthesia or from banked cord blood.

Records to send before travelling

  • Diagnostic pathology and marrow aspirate/biopsy; flow cytometry if available
  • Cytogenetics and molecular tests: karyotype, FISH, NGS or MRD where relevant
  • Recent CBC, platelets, kidney and liver tests, infection results
  • Prior chemotherapy/immunotherapy summary and response to treatment
  • Relevant PET-CT, CT, MRI, operative reports
  • Existing patient or potential donor HLA results; avoid costly new testing before specialist advice

Pre-transplant investigations at the hospital

  • Confirm disease and remission status: CBC, marrow biopsy, MRD/molecular tests as relevant
  • Renal/liver/coagulation tests, iron, blood group and immune status
  • Infection screening: HBV, HCV, HIV, CMV, EBV and others per local policy
  • Cardiac ECG/echo, lung PFT/DLCO and chest imaging when indicated
  • HLA typing and donor medical/infection screening for allogeneic transplants
  • Dental, nutrition, fertility, mental-health and caregiver assessment as appropriate

This is a guide, not a universal prescription. Your transplant team selects tests and dates and may repeat results on arrival.

How a transplant is performed

  1. Specialist review

    Confirm diagnosis, eligibility, options and risks.

  2. Donor matching

    HLA and donor safety evaluation for allogeneic transplant.

  3. Collect stem cells

    Apheresis after mobilisation or pelvic marrow harvest under anaesthesia.

  4. Conditioning

    Chemotherapy and sometimes radiation plus placement of central venous access.

  5. Day zero infusion

    Stem cells enter via an IV catheter, much like a transfusion.

  6. Engraftment monitoring

    Regular blood counts, transfusion and infection support while marrow recovers.

  7. Long-term follow-up

    Monitoring for GVHD, infections, recurrence, medications and revaccination.

Contemporary options to discuss

Haploidentical HSCT with PTCy

Half-matched donor approaches using post-transplant cyclophosphamide for GVHD prevention in selected protocols.

Graft manipulation

TCR αβ depletion and CD45RA depletion are specialised options available in certain centres.

Reduced-intensity conditioning

An option for selected patients who may not tolerate intensive regimens, but risks remain.

MRD-guided risk assessment

Molecular residual-disease monitoring may inform transplant and relapse management.

CAR‑T and donor lymphocyte infusion

CAR‑T is distinct immunotherapy; DLI may be considered after certain donor transplants.

Learn about CAR‑T therapy →

Risks and recovery

  • Infection, bleeding, mouth sores and fatigue during low blood counts
  • Graft failure and GVHD for donor transplants
  • Possible heart, lung or liver injury, infertility and long-term immune effects
  • Stay and recovery duration vary; no fixed success-rate or cost promise applies to every patient

Medical references

NCI · Stem cell transplantEBMT · HandbookEBMT · Pre-HCT testsNMDP · Tests
Request a review of your blood and marrow reportsLearn about CAR‑T therapy

Educational information only; clinical decisions require a transplant team assessment.

Haematology & blood cancers

LeukaemiaLymphoma and multiple myelomaAplastic anaemia and thalassaemiaPlatelet and bleeding disordersAutologous or donor transplantDonor matching and follow-up planning
Autologous transplant uses the patient’s own stem cells when clinically indicated.
Allogeneic transplant uses cells from a compatible donor, including matched or haploidentical options.
Not every blood disorder needs transplantation; medical treatment may be more appropriate.

6 HOSPITALS · 25 SPECIALISTS

Hospitals and specialists

Selected physicians at named hospitals; not a clinical ranking or an endorsement of one doctor for every condition.

Artemis Hospitals, Gurugram

6 doctors
Explore haematology and BMT doctors →

Medanta – The Medicity, Gurugram

6 doctors
Explore haematology and BMT doctors →

Official hospital sources: Max · Fortis · Artemis · Medanta · Apollo

PATIENT CHECKLIST

Preparing your case for review

We coordinate hospital review requests. Diagnosis and clinical decisions remain with the treating team.

Requirements differ by case. Avoid posting sensitive medical records in unsecured public forms.

Request a report review

Reports commonly requested

  • Diagnosis summary and prior treatment
  • Recent CBC and blood tests
  • Bone-marrow biopsy or aspirate, if available
  • Flow cytometry, cytogenetics and molecular testing, if available
  • HLA typing and donor investigations, if already performed